Tirzepatide — CAS 2023788-19-2
Tirzepatide is a fatty-diacid modified dual GIP/GLP-1 receptor agonist peptide supplied as a lyophilized reference material for in-vitro laboratory research. Supplied for laboratory research use only — not for human or veterinary use. Sold only to qualified buyers under our research-use covenant.
| Property | Value |
|---|---|
| CAS Number | 2023788-19-2 |
| Structure | Fatty-diacid modified dual GIP/GLP-1 receptor agonist peptide |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.45 g/mol |
| Vial Sizes Available | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg, 120 mg |
| Price (USD) | 5 mg – $21 · 10 mg – $29 · 15 mg – $37 · 20 mg – $45 · 30 mg – $61 · 40 mg – $73 · 50 mg – $88 · 60 mg – $100 · 80 mg – $130 · 100 mg – $159 · 120 mg – $175 |
| Form | Lyophilized powder, sealed vial |
| Storage | −20 °C, protect from light |
| Purity (HPLC) | 99.77% by HPLC |
| Testing / Lot Reference | Janoshik · Report #206648 (27 Jul 2026) |
This Certificate of Analysis reports identity and purity for the lot referenced above. Purity is stated as percent area by RP-HPLC. See our guide to reading a CoA for what these figures do and do not tell you.
About this reference material
Tirzepatide is supplied by BNM Research Peptides as a lyophilized powder reference material for in-vitro laboratory research. Each lot is supported by lot-specific analytical documentation; testing status, including whether results are independent third-party or manufacturer QC, is disclosed by lot in our public CoA Archive, and the Certificate of Analysis for the lot you receive is traceable to the vial label.
This listing states composition, molecular data, and handling conditions only. We do not publish or provide application, protocol, dosing, or administration information of any kind — see our Research Use Policy for the full terms governing all materials we supply.
Research Background
Tirzepatide is a synthetic peptide that binds and activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). In vitro receptor-pharmacology studies characterize tirzepatide as an imbalanced, biased dual agonist: its activity at GIPR closely resembles native GIP signaling, while its activity at GLP-1R is biased relative to native GLP-1, with reduced recruitment of beta-arrestin relative to cAMP signaling (Willard et al., JCI Insight, 2020). This receptor-binding profile is what distinguishes tirzepatide from single-receptor GLP-1 agonists in the published pharmacology literature.
The literature cited below addresses receptor pharmacology and mechanism only. It does not describe application, dosing, or administration, and is not guidance for any use of this material. See our Research Use Policy.
Testing behind this lot
- How RP-HPLC purity testing works
- Mass spectrometry identity confirmation
- Heavy metals screening
- How to read a Certificate of Analysis
- This lot in the CoA archive (Report #206648)
- Karl Fischer water content
- Net peptide content vs fill weight
- Full quality control panel
For laboratory research use only. Tirzepatide is a chemical reagent supplied exclusively for in-vitro laboratory research by qualified persons. It is not a drug, dietary supplement, food, cosmetic, or medical device, and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or veterinary use.